









Markets
/
Stocks
/
nasdaq-qttb
/

Q32 Bio Inc

QTTB

1.850USD

+0.110+6.32%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

22.57MMarket Cap

LossP/E TTM



Q32 Bio Inc

1.850

+0.110+6.32%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

167 / 506

Overall Ranking

278 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

10.000

Target Price

+474.71%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Q32 Bio Inc. is a clinical-stage biotechnology company. The Company is engaged in developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Its program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase II trials for the treatment of atopic dermatitis and alopecia areata. Its program for innate immunity, ADX-097, is based on a platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade. The Company has completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 853.71.

Overvalued

The company’s latest PE is -0.43, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 9.72M shares, decreasing 33.48% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 269.43K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.79.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.86, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.86

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.79

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.71

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.40, which is 10.46% below the recent high of -0.44 and -370.65% above the recent low of -1.89.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 167/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.33, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Q32 Bio Inc is 8.00, with a high of 20.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

10.000

Target Price

+474.71%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Q32 Bio Inc

QTTB

CRISPR Therapeutics AG

CRSP

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 3.70, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 2.01 and the support level at 1.54, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.70

Change

0.18

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.025

Neutral

RSI(14)

51.130

Neutral

STOCH(KDJ)(9,3,3)

44.057

Neutral

ATR(14)

0.148

Low Volatility

CCI(14)

31.376

Neutral

Williams %R

39.474

Buy

TRIX(12,20)

-0.182

Sell

StochRSI(14)

82.955

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

1.814

Buy

MA10

1.819

Buy

MA20

1.792

Buy

MA50

1.956

Sell

MA100

1.816

Buy

MA200

3.002

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 79.73%, representing a quarter-over-quarter decrease of 5.26%. The largest institutional shareholder is The Vanguard, holding a total of 269.43K shares, representing 2.21% of shares outstanding, with 14.89% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

OrbiMed Advisors, LLC

2.25M

Atlas Venture

2.09M

Abingworth Management Limited

1.10M

Acorn Capital Advisors, LLC

803.42K

Monaco asset management S.A.M.

505.45K

-12.07%

ARCH Venture Partners

320.48K

Pfizer Inc

277.78K

The Vanguard Group, Inc.

Star Investors

309.21K

-2.32%

Sanofi SA

244.08K

Bristol Myers Squibb

200.24K

-73.62%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.93, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.10. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.